Matches in Wikidata for { <http://www.wikidata.org/entity/Q63884022> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- Q63884022 description "article scientifique publié en 2018" @default.
- Q63884022 description "im Februar 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q63884022 description "wetenschappelijk artikel" @default.
- Q63884022 description "наукова стаття, опублікована в лютому 2018" @default.
- Q63884022 name "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 name "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 type Item @default.
- Q63884022 label "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 label "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 prefLabel "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 prefLabel "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 P1433 Q63884022-84563263-E74B-4E14-997D-BC6298EB2F1B @default.
- Q63884022 P1476 Q63884022-E4B9953A-D8ED-42EC-82D6-6E32BA5B8B54 @default.
- Q63884022 P2093 Q63884022-36804EC3-066C-424F-BF70-9CC3A0D04EF2 @default.
- Q63884022 P2093 Q63884022-3880EB7B-2D10-479A-A7F4-5DC21AE13FD6 @default.
- Q63884022 P2093 Q63884022-3D580ECF-CCAD-4374-8786-11556B48E6BA @default.
- Q63884022 P2093 Q63884022-406AE23D-25E3-49EE-80E4-816DD033628A @default.
- Q63884022 P2093 Q63884022-688C7CFF-B0F6-49C2-8A25-85193070A990 @default.
- Q63884022 P2093 Q63884022-6E34A45D-1878-4E16-8E39-600AC7249692 @default.
- Q63884022 P2093 Q63884022-6FB23E7C-6582-45B3-9E60-893472030544 @default.
- Q63884022 P2093 Q63884022-75EAB1DF-ED4E-41F2-AA13-3A482AD8525F @default.
- Q63884022 P2093 Q63884022-7A2C0002-E35B-41B1-A57E-93F37AEF88C4 @default.
- Q63884022 P2093 Q63884022-8524DD48-FB7B-4A3D-9D9E-3AF5D2CDB45E @default.
- Q63884022 P2093 Q63884022-96234E63-1F00-4913-83FB-BEA829D040FE @default.
- Q63884022 P2093 Q63884022-97A5D641-078F-4524-AF22-718AF81DEF59 @default.
- Q63884022 P2093 Q63884022-A89B7A6B-E4D1-464A-A5C7-C213C63C1679 @default.
- Q63884022 P2093 Q63884022-B2947075-88DE-47A4-A4E7-BDE83E8B0750 @default.
- Q63884022 P2093 Q63884022-BA699107-FC2F-4DBA-AC8C-58EE4679F2D3 @default.
- Q63884022 P2093 Q63884022-BB366DEF-6437-4B1C-9525-31C10129F332 @default.
- Q63884022 P2093 Q63884022-BC9FE627-E5AB-4891-84A5-A75D207F8605 @default.
- Q63884022 P2093 Q63884022-BCB91470-E7E9-48B5-AE05-A851865181A0 @default.
- Q63884022 P2093 Q63884022-BDA7B862-2157-4509-B1B5-8A00EAF462E6 @default.
- Q63884022 P2093 Q63884022-BF0AB191-88D6-40FD-A4CA-51BA78C0234B @default.
- Q63884022 P2093 Q63884022-D2BD5C02-2E44-49ED-A054-C0E040EB2592 @default.
- Q63884022 P2093 Q63884022-D9F8BB70-B056-4F92-A412-16C78217B0CB @default.
- Q63884022 P2093 Q63884022-EB542E18-9E08-468D-9DAC-CA4DA73BB537 @default.
- Q63884022 P2093 Q63884022-F310CF5E-3572-41C5-BF4F-C8AD32EB0E86 @default.
- Q63884022 P304 Q63884022-B7C80CD3-F978-4D3D-9726-53CBD3906EF0 @default.
- Q63884022 P31 Q63884022-E4D1AEB9-215D-47C4-A715-E20CE7EBD0BB @default.
- Q63884022 P356 Q63884022-41BBC4B2-8874-4A4E-91B3-FC9923EA7273 @default.
- Q63884022 P407 Q63884022-1A0C27AE-757B-4A1D-901D-48ECC45B07E1 @default.
- Q63884022 P433 Q63884022-354D9D47-4243-4062-8AEC-89E5325D7B3B @default.
- Q63884022 P478 Q63884022-42BC87B3-8FAE-4B1E-A2C8-0A63CC4C36AD @default.
- Q63884022 P50 Q63884022-10F16C5A-97AD-47FF-9840-6C8FE6FD5D93 @default.
- Q63884022 P50 Q63884022-53C45582-844F-4AF5-856A-952377C133A0 @default.
- Q63884022 P50 Q63884022-9D23D5C7-7BC6-4DC9-A680-41ED40B71049 @default.
- Q63884022 P577 Q63884022-CC7084A6-D1A8-45E1-85E7-611FE73D5194 @default.
- Q63884022 P921 Q63884022-2AB660CE-6289-4941-9E01-0BF3075B0AC1 @default.
- Q63884022 P921 Q63884022-65F6B97A-EC57-4356-8F3A-0F3D9C797B56 @default.
- Q63884022 P356 1538-7445.SABCS17-PD5-04 @default.
- Q63884022 P1433 Q326097 @default.
- Q63884022 P1476 "Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea" @default.
- Q63884022 P2093 "A Ballestrero" @default.
- Q63884022 P2093 "A Bardia" @default.
- Q63884022 P2093 "A Jallitsch-Halper" @default.
- Q63884022 P2093 "C Castaneda Altamirano" @default.
- Q63884022 P2093 "C Sanchez" @default.
- Q63884022 P2093 "C Saura" @default.
- Q63884022 P2093 "E Ciruelos" @default.
- Q63884022 P2093 "E de Azambuja" @default.
- Q63884022 P2093 "G Santos Borges" @default.
- Q63884022 P2093 "JM Lombard" @default.
- Q63884022 P2093 "JY Hsu" @default.
- Q63884022 P2093 "K Boer" @default.
- Q63884022 P2093 "L de la Pena" @default.
- Q63884022 P2093 "M Colleoni" @default.
- Q63884022 P2093 "M Fornier" @default.
- Q63884022 P2093 "M Gnant" @default.
- Q63884022 P2093 "M Oliveira" @default.
- Q63884022 P2093 "M Piccart" @default.
- Q63884022 P2093 "P Dubsky" @default.
- Q63884022 P2093 "P Vuylsteke" @default.
- Q63884022 P2093 "S Frantal" @default.
- Q63884022 P2093 "TJ Stout" @default.
- Q63884022 P2093 "TR Wilson" @default.
- Q63884022 P2093 "Y Shi" @default.
- Q63884022 P304 "PD5-04-PD5-04" @default.
- Q63884022 P31 Q13442814 @default.
- Q63884022 P356 "10.1158/1538-7445.SABCS17-PD5-04" @default.
- Q63884022 P407 Q1860 @default.
- Q63884022 P433 "4 Supplement" @default.
- Q63884022 P478 "78" @default.
- Q63884022 P50 Q125261372 @default.
- Q63884022 P50 Q37386010 @default.
- Q63884022 P50 Q6279267 @default.
- Q63884022 P577 "2018-02-14T00:00:00Z" @default.
- Q63884022 P921 Q269829 @default.
- Q63884022 P921 Q42824440 @default.